Related Experiment Video

Updated: Aug 15, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

Potential future therapies for heart failure: gene transfer of beta-adrenergic signaling components

J P Maurice1, W J Koch

  • 1Department of Surgery and Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina 27710, USA.

Coronary Artery Disease
|September 4, 1999
PubMed

Insights

Congestive heart failure (CHF) remains a major challenge, prompting research into new treatments. Gene therapy targeting beta-adrenergic signaling in the heart shows promise for improving outcomes in heart failure patients.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Genetics

Background:

  • Congestive heart failure (CHF) presents ongoing therapeutic challenges with rising mortality rates.
  • Despite advances in cardiovascular disease management, effective treatments for CHF remain limited.
  • Understanding the molecular basis of CHF is crucial for developing novel interventions.

Purpose of the Study:

  • To review beta-adrenergic signaling in the context of CHF.
  • To explore potential gene therapy strategies for treating the failing heart.
  • To highlight advancements in understanding CHF pathogenesis through genetic models.

Main Methods:

  • Review of current literature on beta-adrenergic signaling in CHF.
  • Analysis of experimental data from transgenic mouse models.
  • Discussion of potential gene therapy approaches.

Main Results:

  • Recent studies in transgenic mice elucidate genetic phenotypes related to CHF.
  • These models provide insights into cellular mechanisms of heart failure.
  • Novel gene therapy interventions targeting beta-adrenergic signaling are emerging.

Conclusions:

  • Gene therapy targeting beta-adrenergic signaling offers a promising avenue for improving cardiac function in CHF.
  • Further research into genetic modifications could lead to more effective treatments for heart failure.
  • Understanding molecular pathways is key to advancing CHF therapies.

More Related Videos

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart06:07

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart

Published on: September 2, 2021

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...